Últimas noticias sobre Pacira BioSciences (NASDAQ:PCRX) Bolsa

Pacira BioSciences

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.

Pacira BioSciences Inc

Biotech

News

General

PCRX

Pacira Reports 104-Week Safety And Efficacy Data Following Local Administration Of PCRX-201 For Moderate To Severe Osteoarthritis Of Knee

Barclays analyst Balaji Prasad maintains Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) with a Equal-Weight and lowers the price target from $25 to $17.

Price Target

Analyst Ratings

Barclays Maintains Equal-Weight on Pacira BioSciences, Lowers Price Target to $17

Needham analyst Serge Belanger reiterates Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) with a Buy and maintains $22 price target.

Reiteration

Needham Reiterates Buy on Pacira BioSciences, Maintains $22 Price Target

Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $17.75, a high estimate of $39.00, and a low estimate of $8.00. This current average has decreased by 44.53% from the previous average price target of $32.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1731009644_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of Pacira BioSciences by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$16.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Glen Santangelo</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$18.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Les Sulewski</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Sell</td>
<td>$8.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$14.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$39.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$22.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Hardik Parikh</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$10.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Pacira BioSciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Pacira BioSciences compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Pacira BioSciences's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Pacira BioSciences's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PCRX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Pacira BioSciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Pacira BioSciences: A Closer Look</h2>
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
<h3>Pacira BioSciences: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining Pacira BioSciences's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 5.05% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Pacira BioSciences's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.61% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.13%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Pacira BioSciences's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.17% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Pacira BioSciences's debt-to-equity ratio is below the industry average at 0.74, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Evaluating Pacira BioSciences: Insights From 8 Financial Analysts

RBC Capital analyst Gregory Renza maintains Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) with a Sector Perform and raises the price target from $15 to $16.

RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $16

2024 Financial Guidance
Today the company is reiterating its full-year 2024 financial guidance as follows:
<ul>
<li>Total revenue of $680 million to $705 million;</li>
<li>Non-GAAP gross margin of 74% to 76%;</li>
<li>Non-GAAP R&amp;D expense of $70 million to $80 million;</li>
<li>Non-GAAP SG&amp;A expense of $245 million to $265 million; and</li>
<li>Stock-based compensation of $50 million to $55 million.</li>
</ul>

Guidance

Pacira BioSciences Sees FY24 Revenue $680M-$705M Vs $692.7M Estimate

Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) reported quarterly earnings of $0.83 per share which beat the analyst consensus estimate of $0.70 by 18.57 percent. The company reported quarterly sales of $168.600 million which missed the analyst consensus estimate of $169.672 million by 0.63 percent. This is a 2.85 percent increase over sales of $163.926 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Pacira BioSciences Q3 2024 Adj. EPS $0.83 Beats $0.70 Estimate, Sales $168.600M Miss $169.672M Estimate

Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) is gearing up to announce its quarterly earnings on Wednesday, 2024-11-06. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Pacira BioSciences will report an earnings per share (EPS) of $0.70.
Anticipation surrounds Pacira BioSciences's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Overview of Past Earnings</h3>
Last quarter the company beat EPS by $0.19, which was followed by a 5.68% increase in the share price the next day.
Here's a look at Pacira BioSciences's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.70</td>
<td>0.62</td>
<td>0.88</td>
<td>0.79</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.89</td>
<td>0.62</td>
<td>0.89</td>
<td>0.72</td>
</tr>
<tr>
<td>Price Change %</td>
<td>6.0%</td>
<td>12.0%</td>
<td>-3.0%</td>
<td>6.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730818942_0.png" alt="eps graph" />
<h3>Tracking Pacira BioSciences's Stock Performance</h3>
Shares of Pacira BioSciences were trading at $16.45 as of November 04. Over the last 52-week period, shares are down 45.22%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analyst Observations about Pacira BioSciences</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Pacira BioSciences.
Analysts have given Pacira BioSciences a total of 7 ratings, with the consensus rating being Buy. The average one-year price target is $18.0, indicating a potential 9.42% upside.
<h3>Understanding Analyst Ratings Among Peers</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of EyePoint Pharmaceuticals, Liquidia and Phibro Animal Health, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>The consensus outlook from analysts is an Buy trajectory for EyePoint Pharmaceuticals, with an average 1-year price target of $24.0, indicating a potential 45.9% upside.</li>
<li>The prevailing sentiment among analysts is an Buy trajectory for Liquidia, with an average 1-year price target of $26.08, implying a potential 58.54% upside.</li>
<li>Phibro Animal Health received a Neutral consensus from analysts, with an average 1-year price target of $18.5, implying a potential 12.46% upside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
The peer analysis summary provides a snapshot of key metrics for EyePoint Pharmaceuticals, Liquidia and Phibro Animal Health, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pacira BioSciences</td>
<td>Buy</td>
<td>5.05%</td>
<td>$133.76M</td>
<td>2.13%</td>
</tr>
<tr>
<td>EyePoint Pharmaceuticals</td>
<td>Buy</td>
<td>4.09%</td>
<td>$8.08M</td>
<td>-12.89%</td>
</tr>
<tr>
<td>Liquidia</td>
<td>Buy</td>
<td>-23.55%</td>
<td>$2.17M</td>
<td>-37.51%</td>
</tr>
<tr>
<td>Phibro Animal Health</td>
<td>Neutral</td>
<td>7.10%</td>
<td>$87.15M</td>
<td>0.29%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Pacira BioSciences ranks at the top for Revenue Growth and Gross Profit among its peers. However, it ranks at the bottom for Return on Equity.
<h3>All You Need to Know About Pacira BioSciences</h3>
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
<h3>Financial Insights: Pacira BioSciences</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining Pacira BioSciences's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 5.05% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Pacira BioSciences's net margin is impressive, surpassing industry averages. With a net margin of 10.61%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Pacira BioSciences's ROE stands out, surpassing industry averages. With an impressive ROE of 2.13%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Pacira BioSciences's ROA excels beyond industry benchmarks, reaching 1.17%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.74.
<a href="https://www.benzinga.com/quote/PCRX/earnings">To track all earnings releases for Pacira BioSciences visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights into Pacira BioSciences's Upcoming Earnings

Pacira BioSciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the appointment of Shawn Cross as Chief Financial Officer. In this role, Mr. Cross will be responsible for overseeing all aspects of the company's financial operations.

Management

Pacira BioSciences Appoints Shawn Cross As Chief Financial Officer

RBC Capital analyst Gregory Renza maintains Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) with a Sector Perform and raises the price target from $14 to $15.

RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $15

-- New J-code issued by the Centers for Medicare and Medicaid Services expected to standardize and streamline billing and reimbursement -- &nbsp;
TAMPA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced that the&nbsp;Centers for Medicare and Medicaid Services&nbsp;(CMS) has established a permanent product-specific Healthcare Common Procedure Coding System (HCPCS) J-code for EXPAREL&#xAE; (bupivacaine liposome injectable suspension). The new J-code for EXPAREL, J0666, becomes effective January 1, 2025, and will supersede the current C-code (C9290), which has been in place since 2019.
In addition to the separate CMS reimbursement EXPAREL will receive in outpatient settings with the implementation of NOPAIN in January 2025, this new J-code will also provide reimbursement when EXPAREL is used in the office setting and for office-based surgeries.

Pacira BioSciences Announces New Product-Specific J-Code For EXPAREL Effective January 1, 2025

Pacira To Present 104-Week Safety And Efficacy Data On PCRX-201 Gene Therapy For Moderate-To-Severe Knee Osteoarthritis At ACR Convergence; Data Show Sustained Clinical Effects After Single Intra-Articular Injection

Believes Pacira's Cash Balance of $400 million, Roughly 59% of its Market Capitalization, is Grossly Inefficient.
Emphasizes the Current Stock Price Offers an Extraordinary Opportunity to Create Meaningful Return for Shareholders
MIAMI, Sept. 25, 2024 /PRNewswire/ --&nbsp;DOMA Perpetual Capital Management LLC today sent a letter to the Board of Directors of Pacira Biosciences (NYSE:&nbsp;PCRX) urging the Board to accelerate and increase its stock repurchase.&nbsp;
 &nbsp;

Dividends

Buybacks

DOMA Perpetual Sends Letter To Board of Directors Of Pacira Biosciences To Immediately Accelerate And Increase Its Share Buyback Program To Enhance Return To Shareholders; Believes Pacira's Cash Balance Of $400M, Roughly 59% of its Market Capitalization, is Grossly Inefficient

In the latest quarter, 14 analysts provided ratings for Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>), showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Pacira BioSciences, presenting an average target of $30.36, a high estimate of $57.00, and a low estimate of $8.00. A 26.47% drop is evident in the current average compared to the previous average price target of $41.29. 
<img src="https://www.benzinga.com/files/images/story/2024/1727193634_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive Pacira BioSciences is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glen Santangelo</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$18.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Les Sulewski</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Sell</td>
<td>$8.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$14.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$39.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$22.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Hardik Parikh</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$10.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Gary Nachman</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$37.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$37.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$43.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Les Sulewski</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$30.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$25.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$43.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$57.00</td>
<td>$57.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Pacira BioSciences. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Pacira BioSciences compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into Pacira BioSciences's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PCRX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Pacira BioSciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Pacira BioSciences</h2>
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
<h3>Pacira BioSciences: Financial Performance Dissected</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Pacira BioSciences's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 5.05%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Pacira BioSciences's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.61% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Pacira BioSciences's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.13% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Pacira BioSciences's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.17% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Pacira BioSciences's debt-to-equity ratio is below the industry average at 0.74, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Ratings For Pacira BioSciences

Jefferies analyst Glen Santangelo maintains Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) with a Buy and raises the price target from $15 to $18.

Jefferies Maintains Buy on Pacira BioSciences, Raises Price Target to $18

Truist Securities analyst Les Sulewski downgrades Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) from Buy to Sell and lowers the price target from $30 to $8.

Downgrades

Truist Securities Downgrades Pacira BioSciences to Sell, Lowers Price Target to $8

Friday,&nbsp;Pacira BioSciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) announced that the U.S. District Court for the District of New Jersey found that the company&#8217;s U.S. Patent No. 11,033,495 (the ‘495 patent) <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/g40293827/pacira-biosciences-comments-on-ruling-on-exparel-patent-litigation-from-u-s-district-court-for-the" rel="noreferrer noopener">is not valid</a>.
&#8220;We remain steadfast in our belief in the strength and validity of our intellectual property and that eVenus is infringing upon our patents,&#8221; said Frank D. Lee, chief executive officer of Pacira BioSciences. &#8220;In light of the Court&#8217;s decision, we are considering our legal options, which include pursuing an appellate review at the U.S. Court of Appeals for the Federal Court as warranted.&#8221;
In November 2021, Pacira BioSciences <a target="_blank" href="https://investor.pacira.com/news-releases/news-release-details/pacira-files-lawsuit-against-evenus-patent-infringement" rel="noreferrer noopener">filed</a> a lawsuit in the United States District Court for the District of New Jersey against eVenus Pharmaceutical Laboratories, Inc. for patent infringement of U.S. Patent Number 11,033,495.
The '495 patent is related to Exparel&nbsp;(bupivacaine liposome injectable suspension) and expires on January 22, 2041.
Exparel is Pacira BioSciences&#8217; non-opioid analgesic pain management and is indicated for postsurgical analgesia.
The complaint sought an injunction to prevent the infringing manufacture, use, and sale of a potential generic product described in an Abbreviated New Drug Application that eVenus filed with the FDA in August 2021.
JP Morgan &#8220;previewed that an unfavorable ruling for Pacira was the most likely outcome, but this ruling is clearly the worst-case scenario&#8230;&#8221; The stock fell more than 40% on Friday after the ruling.
Exparel accounts for almost 80% of Pacira BioSciences&#8217; revenues, which can be eroded due to a lack of patents.
In the second quarter, Exparel sales reached $136.9 million, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/g40049670/pacira-biosciences-reports-second-quarter-2024-financial-results" rel="noreferrer noopener">versus $135.1 million a year ago</a>, of the total sales of $178.0 million.
Contracted discounts and vial mix offset the second quarter volume growth of 3%.
&#8220;It is also the main source of growth as the company&#8217;s other two assets are relatively immaterial, and the Street doesn&#8217;t ascribe much value to the company&#8217;s R&amp;D pipeline,&#8221; JP Morgan commented on Exparel.
Amid the lack of a clear path to recovery for Pacira BioSciences shares, JP Morgan has downgraded to Underweight from Overweight, with a price target of $10, reduced from the <a target="_blank" href="https://www.benzinga.com/quote/PCRX/analyst-ratings" rel="noreferrer noopener">prior price target of $45</a>.
Price Action: PCRX stock is up 5.13% at $12.30&nbsp;at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/08/40319861/noninvasive-treatment-provider-neuronetics-agrees-to-merge-with-canadian-firm-greenbrook-tms-report" target="_blank" rel="noreferrer noopener">Noninvasive Treatment Provider Neuronetics Agrees To Merge With Canadian Firm Greenbrook TMS; Reports Q2 Earnings And Guidance Below Expectations</a>.</li>
</ul>

Analyst Color

Equities

Health Care

Legal

Movers

Trading Ideas

Pain Management-Focused Pacira BioSciences Loses Patent Fight For Key Drug, JP Morgan Analyst Downgrades On Unclear Path

In the latest quarter, 12 analysts provided ratings for Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $33.25, a high estimate of $57.00, and a low estimate of $10.00. A decline of 25.15% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1723485647_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The perception of Pacira BioSciences by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$14.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$39.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$22.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Hardik Parikh</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$10.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Gary Nachman</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$37.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$37.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$43.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Les Sulewski</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$30.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$25.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$43.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$57.00</td>
<td>$57.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Pacira BioSciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Pacira BioSciences compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of Pacira BioSciences's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/PCRX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Pacira BioSciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Pacira BioSciences Better</h2>
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
<h3>Pacira BioSciences: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Pacira BioSciences displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 5.05%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Pacira BioSciences's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.61% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Pacira BioSciences's ROE excels beyond industry benchmarks, reaching 2.13%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.17%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.74, Pacira BioSciences adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Pacira BioSciences Stands With Analysts

RBC Capital analyst Gregory Renza downgrades Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) from Outperform to Sector Perform and lowers the price target from $37 to $14.

RBC Capital Downgrades Pacira BioSciences to Sector Perform, Lowers Price Target to $14

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 50 points on Monday.
Shares of JetBlue Airways Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) fell sharply in today's pre-market trading after the company announced a $400 million convertible senior notes offering.
JetBlue Airways shares dipped 5.6% to $5.71 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>iLearningEngines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AILE#NASDAQ">AILE</a>) shares declined 25.8% to $4.29 in pre-market trading. ILearningEngines will report financial results for the second quarter before the opening bell on Tuesday, Aug. 13.</li>
<li>B. Riley Financial, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RILY#NASDAQ">RILY</a>) fell 25% to $12.70 in pre-market trading after the company reported preliminary second-quarter financial results.</li>
<li>Hawaiian Electric Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HE#NYSE">HE</a>) dipped 7.7% to $14.28 pre-market trading after the company reported weak second-quarter earnings.</li>
<li>Fortrea Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) fell 6.5% to $23.53 in pre-market trading after the company posted downbeat second-quarter results and lowered its FY24 revenue guidance.  </li>
<li>Pagaya Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGY#NASDAQ">PGY</a>) shares declined 6% to $13.37 in pre-market trading. The company reported second-quarter results on Friday.</li>
<li>Pacira BioSciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) fell 4.4% to $11.18 in pre-market trading. JP Morgan analyst Hardik Parikh downgraded Pacira BioSciences from Overweight to Underweight and lowered the price target from $45 to $10.</li>
<li>Marathon Digital Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) fell 3.5% to $16.44 as the company announced a proposed private offering of $250 million of convertible senior notes.</li>
</ul>
Now Read This: &lt;a href=&#8221;https://www.benzinga.com/trading-ideas/long-ideas/24/04/38311966/izea-worldwide-and-2-other-stocks-under-3-insiders-are-buying&#8221;&gt;&lt;em&gt; IZEA Worldwide And 2 Other Stocks Under $3 Insiders Are Buying &lt;/em&gt;&lt;/a&gt;

Pre-Market Outlook

Markets

AILE

FTRE

JBLU

MARA

RILY

JetBlue Airways, B. Riley Financial, Hawaiian Electric And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Executive reshuffles: MS, HSBC and TXT

Pacira (PCRX) BioSciences announced that the Centers for Medicare and Medicaid Services, CMS, issued its final Medicare Hospital Outpatient Prospec...

Pacira announces CMS established additional payment for iovera in outpatient

Pacira BioSciences Q3 2024 Earnings Preview

Pacira Biosciences Inc. (PCRX) Q3 2024 Earnings Call Transcript

Pacira ( ($PCRX) ) has released its Q3 earnings. Here is a breakdown of the information Pacira presented to its investors. Pacira BioSciences, Inc....

Pacira BioSciences Reports Q3 2024 Earnings and Strategic Developments

Pacira BioSciences Non-GAAP EPS of $0.79 beats by $0.09, revenue of $168.6M misses by $9.43M

Pacira Pharmaceuticals (PCRX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Serge Belange...

Positive Outlook for Pacira Pharmaceuticals Despite Mixed Q3 2024 Results, Driven by Exparel's Strong Market Position and Strategic Initiatives

In a report released today, Balaji Prasad from Barclays maintained a Hold rating on Pacira Pharmaceuticals (PCRX – Research Report), with a price t...

Barclays Reaffirms Their Hold Rating on Pacira Pharmaceuticals (PCRX)

Barclays analyst Balaji Prasad lowered the firm's price target on Pacira (PCRX) to $17 from $25 and keeps an Equal Weight rating on the shares. The...

Pacira price target lowered to $17 from $25 at Barclays

Pacira (PCRX) BioSciences announced new data demonstrating its gene therapy for osteoarthritis candidate, PCRX-201, provided sustained improvements...

Pacira announces 104-week safety, efficay data for PCRX-201

HSBC

PHUN

REXR

Press Releases

DOMA Perpetual Sends Letter to Board of Directors of Pacira Biosciences to Immediately Accelerate and Increase its Share Buyback Program to Enhance Return to Shareholders

Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee

Comments

Pacira BioSciences

Noticias

Últimas noticias sobre Pacira BioSciences (NASDAQ:PCRX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL